PMD News and Press, Psychemedics Corporation From 11/27/23

ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for...

ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Psychemedics Corporation (PMD) is expected to report for Q1 2024

ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform ...

ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseei...

ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering...

2023-08-11 17:40:41 ET Psychemedics press release ( NASDAQ: PMD ): Q2 GAAP EPS of -$0.13. Revenue of $5.54M (-14.9% Y/Y). For further details see: Psychemedics GAAP EPS of -$0.13, revenue of $5.54M

ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended Ju...

2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% .  Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...